Tags Posts tagged with "Hemp"

Hemp

0 996

Since growing hemp has been illegal for almost a full century, researchers have been unable to learn all the benefits associated with it. Hemp is a distinct variety of the cannabis plant but it is not the same as marijuana. Although hemp is commonly associated with marijuana, it should not be.

 

The benefits associated with hemp are endless. Several products which are used by people every day can be created from hemp. These include paper, clothing, building materials, fuel, and nutrition.

 

The best part about growing hemp is the conditions which it can grow under. If you look at pictures of New York from the mid-1900s, hemp was growing everywhere. Hemp has multiple growing seasons and it can be grown in some of the toughest environments. Researches have estimated that the Florida hemp industry could be a $460 million-dollar industry per year.

 

Capitalizing on Hemp

 

Industrial hemp and marijuana are two completely different plants, inside and out. Hemp contains a very small amount (less than 1%) of tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana (the chemical that gets a user high). Legal cannabis has a much larger amount of THC (between 15%-30%).

 

The surge in the number of publicly traded cannabis companies has made it difficult for investors to focus on legitimate investments in the industry. One of these is a NYSE-traded holding company, Compass Diversified Holdings (CODI).

 

The company offers investors the opportunity to invest in a company levered to the industrial hemp industry and offers a dividend.

 

What Does Compass Do?

 

Compass owns and manages a diverse family of established North American middle market businesses. In July, CODI finalized the acquisition of Fresh Hemp Foods Ltd., for $132.5 million (CAD) and sold its CamelBak Products, LLC subsidiary to Vista Outdoor Inc.

 

Fresh Hemp was founded in 1998 in Winnipeg, Canada and operates under the name Manitoba Harvest. The company produces and sells its products online and through retail stores in North America. Manitoba offers hemp hearts, heart bites, protein powders, oils, and food starter packs.

 

Manitoba’s products are currently carried in approximately 7,000 retail stores across the United States and Canada. During the fiscal year that ended on November 30, 2014, the company generated $37.9 million (CAD) in revenue, which represents a 23.9% increase on a year-over-year basis. Manitoba has continued to see significant revenue growth during the first half of its current fiscal year and they generated $27.6 million of revenue during this time.

 

CODI offers investors an 8.3% dividend yield or $1.44 in cash distributions per year. The company’s dividend has grown consistently over the years and its financial stability is secure, especially after the sale of its CamelBak subsidiary.

 

0 799

CHEYENNE, Wyo., Jan. 31, 2017  — FBEC Worldwide, Inc. (FBEC), a lifestyle brand company with a focus on Healthy Hemp Energy™ & CBD infused consumer products, is pleased to announce that on January 5, 2017 FBEC Worldwide, Inc. entered a new co-packing agreement with NVE Pharmaceuticals, the manufacturer of Stacker 2. NVE will produce FBEC’s proprietary 2oz energy shots using NVE’s custom ingredients and FBEC’s hemp juice powder.

CEO Jeff Greene stated, “NVE will allow us to increase production, quality & efficiency while reducing cost per bottle by up to 40% allowing for greater profit margins, for FBEC. NVE’s experience in the industry and the success & experience they have had with their product, Stacker 2, will no doubt be an asset as we move forward in 2017.”

About NVE Pharmaceuticals:

NVE Pharmaceuticals is a leader in manufacturing herbal dietary supplements that have helped consumers with their diet and energy needs. NVE Pharmaceuticals, the Diet & Energy Specialists, continue to expand their reach into cutting edge research, development and private label manufacturing. Nationally known Stacker 2 and Stacker 3 commands a very strong and reliable presence in the market place today. Time proven success stories and exceptional manufacturing have been the cornerstone of the company. More info on NVE Pharmaceuticals: http://nveusa.com/

About FBEC Worldwide, Inc.

FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp Energy™ & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on several major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships.

FBEC Worldwide is currently developing and building Healthy Hemp™ & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Investor Relations Contact:

Joe Sirianni
MIDAM Ventures LLC
(305) 707-7018
jsirianni@MidamIr.com
www.MIDAMIr.com

0 1600

A notice published last month in the Federal Register by the United States Drug Enforcement Administration (DEA) has formed varied reactions in the growing CBD (cannabidiol) industry and may soon result in a court battle over the legality of a substance that federal law enforcement considers a marijuana extract. The DEA reported a final rule to create a new Administration Controlled Substances Code Number for marijuana extract in December, clarifying in response to a comment submitted to the agency that CBD would fall within the new drug code. Marijuana extracts will remain a Schedule 1 controlled substance. The DEA explained the new drug policy would enable the agency to track quantities of cannabis extract separately.

The DEA said in the notice, “The creation of a new drug code in the DEA regulations for ‘marijuana’ extracts will allow for more appropriate accounting of such materials consistent with treaty provisions.” Hemp lawyers have disputed the DEA’s rule is inconsistent to the 2014 Farm Bill signed by Former President Barack Obama. Section 7606 of the 2014 Farm Bill authorized the growth and farming of industrial hemp, from which CBD seemingly derives. However, the notice raised worry that the DEA would move to crack down on producers and marketers of CBD, which has been researched as a medicine to treat epilepsy and widely marketed in dietary supplements.

Worried that CBD would be treated as a Schedule 1 narcotic, Jonathan Miller, a lawyer in Lexington, KY, with the firm Frost Brown Todd LLC, described as “apocalyptic” some initial reactions in the industry to DEA’s notice. “DEA cannot rewrite federal law, and federal law is very clear, particularly. Hemp that is grown pursuant to a pilot program, that the Controlled Substances Act is exempted,” Miller said in a phone interview. “We do not feel the DEA rule changes anything, especially for people who are part of hemp pilot programs,” Miller stated.

Yet, some hemp leaders are getting ready for a possible legal battle with the DEA in response to its notice. The new drug code is expected to take effect soon. The Hemp Industries Association stated last month in a press release, “The DEA final rule is concerning to the industry, as it creates confusion in the marketplace among consumers and legitimate businesses alike, and may potentially result in federal agencies improperly treating legal products such as CBD oils, body balms, and supplements as controlled substances.” The trade group added it was “strongly considering legal action” to protect the hemp industry.

0 11440

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

0 1696

Pennsylvania growers are being encouraged to share in a newly developed pilot research program that will add toward a better knowledge of what could be a new cash crop in the state. Secretary of Agriculture Russell Redding stated, “Hemp has a long history here in Pennsylvania, and we believe it holds a promising future. If we want to realize this crop’s full potential, though, we need the benefit of sound research.”

Industrial hemp was grown commercially in the United States until after World War II. Governments began to outlaw its cultivation in the mid-20th century because of its association with marijuana. Pennsylvania joins states like Kentucky and New York where officials and growers are keeping their focus on the seemingly profitable future of hemp growth. The Department of Agriculture will award $1,000 to successful hemp research program permit recipients to balance out the costs of the project under the cost-share program.

Grain farmer Ammon Carlyle is intrigued by the program. He stated, “I looked up ‘hemp’ online and learned that early in the country’s history it was widely grown and was a way that farmers made money. I plan to make an application to join the project.” Carlyle definitely has the land to hold the project.

Researchers who finish a hemp research project are qualified to apply, as long as the project has been approved by the Department of Agriculture. Under the Industrial Hemp Pilot Research Program guidelines, a maximum of thirty projects of five acres each will be selected for the 2017 growing season. The department will select the projects based on a complete program application. The department will issue a research permit to an institution of higher education or to a person contracted to grow industrial hemp for research purposes. The pilot research program follows the state and federal laws that allow industrial hemp to be grown in states where allowed.

The cut off date for Pennsylvania growers to apply for a 2017 PDA Industrial Hemp Research Pilot Program was January 6. Applicants who are approved for research projects will be notified by February 17.

0 2013

The Kentucky Department of Agriculture has accepted over 200 applications from farmers who have been given the ok to cultivate up to almost 13,000 acres of industrial hemp for research purposes in 2017. Over 525,000 square feet of greenhouse space were approved for indoor growers, as well.

Agriculture Commissioner Ryan Quarles stated, “By nearly tripling hemp acreage in 2017 and attracting more processors to the state, we are significantly growing opportunities for Kentucky farmers. Our strategy is to use Kentucky’s Department of Agriculture’s research pilot program to encourage the industrial hemp industry to expand and prosper in the state.” He continued, “Although it is not clear when Congress might act to remove industrial hemp from the list of controlled substances, my strategic objective is to position the Commonwealth’s growers and processors to ultimately prevail as national leaders in industrial hemp production.”

The Kentucky Department of Agriculture received just over 250 applications. Applicants were asked to identify which harvestable component of the plant would be the focus of their research: grain, floral material, or fiber. Some applicants selected more than one. Five universities will conduct additional research in 2017. The department officials named the recent decline in commodity prices as a factor that appears to be generating increased interest among growers in industrial hemp. In 2016, just under 140 growers were accepted to plant up to 4,500 acres. Program participants planted more than 2,300 acres of hemp in 2016, up from 922 acres in 2015 and 33 acres in 2014.

To enhance the department’s association with local and state law enforcement officers, KDA will add GPS coordinates of approved industrial hemp planting sites to law enforcement agencies before any hemp is planted. GPS coordinates were required to be submitted on the application. Applicants also must pass background checks and consent to allow program staff and law enforcement officers to inspect any location where hemp or hemp products are being handled, processed, or grown.

Quarles stated, “We have made collaboration and communication with the law enforcement community a top priority for KDA’s management of this research pilot program.” Staff with the KDA’s industrial hemp research pilot program assessed the applications and considered whether returning applicants had complied with instructions from KDA, local law enforcement, and Kentucky State Police. To advertise clarity and ensure a fair playing field while evaluating applications, The Kentucky Department of Agriculture relied on objective criteria outlined in the 2017 Policy Guide.

0 1339

Pennsylvania growers are being encouraged to share in a newly developed pilot research program that will add toward a better knowledge of what could be a new cash crop in the state. Secretary of Agriculture Russell Redding stated, “Hemp has a long history here in Pennsylvania, and we believe it holds a promising future. If we want to realize this crop’s full potential, though, we need the benefit of sound research.”

Industrial hemp was grown commercially in the United States until after World War II. Governments began to outlaw its cultivation in the mid-20th century because of its association with marijuana. Pennsylvania joins states like Kentucky and New York where officials and growers are keeping their focus on the seemingly profitable future of hemp growth. The Department of Agriculture will award $1,000 to successful hemp research program permit recipients to balance out the costs of the project under the cost-share program.

Grain farmer Ammon Carlyle is intrigued by the program. He stated, “I looked up ‘hemp’ online and learned that early in the country’s history it was widely grown and was a way that farmers made money. I plan to make an application to join the project.” Carlyle definitely has the land to hold the project.

Researchers who finish a hemp research project are qualified to apply, as long as the project has been approved by the Department of Agriculture. Under the Industrial Hemp Pilot Research Program guidelines, a maximum of thirty projects of five acres each will be selected for the 2017 growing season. The department will select the projects based on a complete program application. The department will issue a research permit to an institution of higher education or to a person contracted to grow industrial hemp for research purposes. The pilot research program follows the state and federal laws that allow industrial hemp to be grown in states where allowed.

The cut off date for Pennsylvania growers to apply for a 2017 PDA Industrial Hemp Research Pilot Program was January 6. Applicants who are approved for research projects will be notified by February 17.

0 2590

Farmers are planting less tobacco in Kentucky after growing health concerns decreased demand. Alternatively, they’re increasingly turning to hemp and have more than doubled the cannabis variety types in 2016. The states has become the Number 2 producer in the United States, right behind Colorado.

Giles Shell, who cultivates with his dad and brother 45 minutes south of Lexington on a 200 acre farm said, “The profit is promising,” The family plans to dedicate 80 acres to hemp next year, land that for four generations was used to produce tobacco. “We’ve been willing as a family farm to be able to take this adventure.”

There were strict controls on hemp among anti-drug sentiment over the last few decades, making it illegal to grow without a government permit as the plant got tied in with cannabis. The United States farm bill authorized agriculture departments to create industrial hemp research pilot programs in 2014. This reopened production opportunities. According to the state’s agriculture department, only 33 acres were planted in Kentucky that year. According to the state’s agriculture department, plants rose to 922 acres in 2015 and skyrocketed to over 2,300 acres in 2016.

According to the department, the state’s first hemp crop was grown in 1775, and almost all of the country’s production was grown in the Bluegrass region following the Civil War. The crop was included with federal legislation that outlawed marijuana harvesting in 1938, and output decreased to almost nothing following the Second World War.

Doris Hamilton, the industrial hemp program manager for Kentucky’s agriculture department, said cultivators are seeking alternatives as prices for other commodities remain grim and the tobacco market continues to decline.

Steenstra stated that most of the hemp products sold in the United States are being imported from other countries. Farmers now have an opportunity to get a foot in the market as the demand rises.

0 2007

Right after the DEA decided to classify cannabis extracts (in particular classifying CBD, hemp and all their derivatives as Schedule 1 substances), the Hemp Industries Association (HIA) stated Monday that it’s “strongly considering legal action” to stop the DEA’s move.

The HIA is saying that CBD products should be classified as “supplements,” not drugs or pharmaceuticals. They said the DEA abused its authority. Stating that Congress or the U.S. attorney general are the only ones authorized to add CBD oil to the list of banned substances.

The non-profit trade association who represents businesses, farmers, researchers and investors working with industrial hemp, stated in a press release that the DEA was not right in classifying all CBD products as “marijuana extracts” considering the oil can be made from both marijuana and hemp plants.

“Additionally, the ruling is based on an incorrect and incomplete understanding of how CBD is derived from the cannabis plant,” the HIA said in a statement. “While CBD may be derived from forms of cannabis that contain high amounts of THC, the cannabinoid associated with ‘marijuana,’ CBD may also be produced from industrial hemp plants that meet the legal standards of less than 0.3 percent THC by dry weight, and which may be cultivated in 32 states in the U.S. per Sec. 7606 of the Farm Bill. Hence, not all CBD products may be classified as extracts from ‘marijuana.’”

Executive director of HIA; Eric Steenstra, says that Congress already ruled on the subject when they allowed hemp farmers to produce CBD oil in a bunch of states under the 2014 farm bill.

Steenstra reiterated that the “DEA has no authority whatsoever to impede the production, processing or sale of hemp products, including CBD products, grown under the Farm Bill.”

In the meantime; a finding presented by researchers at the American Epilepsy Society’s 70th Annual Meeting in early December discovered that CBD oil reduces the amount and severity of seizures in children and adults with severe, intractable epilepsy.

“Our research adds to the evidence that CBD may reduce frequency of seizures, but we also found that it appears to decrease the severity of seizures, which is a new finding,” said Jerzy P. Szaflarski, M.D., Ph.D., professor in the department of neurology and director of the Birmingham Epilepsy Center at the University of Alabama, who was at the meeting.

0 1181

In a milestone that signifies growth for its hemp market; Colorado becomes the first state in the nation to make certified seeds for industrial hemp. As per federal law, a pot plant must contain 0.3 percent or less Tetrahydrocannabinol (THC), to be classified as hemp. THC is the determining factor that classifies a pot plant as hemp or marijuana. Textiles, paper, plastics, solar panels and biofuel can be made from hemp. Hemp seeds can be utilized to process a wide variety of food products such as: bread and milk. It can also be used as livestock feed.

Marijuana derived CBD is only legal in states which have legalized medical marijuana; however, hemp derived CBD is legal in all 50 states. According to CBD advocates, CBD oil is safe for children and has been praised as a treatment for a variety of diseases and disorders. As per Duane Sinning, assistant director for plant industry at the Colorado Department of Agriculture; approximately 30 states allow some type of hemp production, but none of them have certified seed. Certification signifies the seed was tested in all growing conditions possible statewide and the plants met the 0.3 percent or less THC maximum.

Approximately 260 growers in Colorado are cultivating hemp in 400 locations per Sinning. During the first year there was 200 acres planted with another 250,000 square feet of indoor hemp growing. In 2016 there is currently 6,000 acres planted as well as 1.3 million square feet of indoor cultivation. As per Sinning, it is important to have certified seed because if you buy uncertified seed you do not know until after it grows, whether or not it will pass that crucial 0.3 percent test. If you exceed 0.3 percent; it is no longer considered hemp, under federal law it is marijuana.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements